๐ข ๐๐๐๐ ๐๐: $Viking Therap(VKTX.US) Viking Therapeutics Launches Phase 1 Trial for New Weight-Loss Drug VK3019
๐ ๐๐๐ฒ ๐๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:โค ๐๐ข๐ค๐ข๐ง๐ ๐๐ก๐๐ซ๐๐ฉ๐๐ฎ๐ญ๐ข๐๐ฌ initiated a ๐๐ก๐๐ฌ๐ ๐ trial of weight-loss candidate VK3019.โค VK3019 is a ๐๐ฎ๐๐ฅ ๐๐ฆ๐ฒ๐ฅ๐ข๐ง and ๐๐๐ฅ๐๐ข๐ญ๐จ๐ง๐ข๐ง receptor agonist (DACRA).โค Trial follows ๐ ๐๐ clearance of VK3019's Investigational New Drug application.โค Study will evaluate ๐ฌ๐๐๐๐ญ๐ฒ, ๐ญ๐จ๐ฅ๐๐ซ๐๐๐ข๐ฅ๐ข๐ญ๐ฒ, and pharmacokinetics in adults with BMI โฅ 30.โค Exploratory assessments include changes in ๐๐จ๐๐ฒ ๐ฐ๐๐ข๐ ๐ก๐ญ after a single dose.โค Preclinical data showed up to ๐% ๐๐จ๐๐ฒ-๐ฐ๐๐ข๐ ๐ก๐ญ reduction within 72 hours in animal studies.โค Viking is also conducting ๐๐ก๐๐ฌ๐ ๐ VANQUISH trials for obesity drug VK2735.โค Company plans to launch a ๐๐ก๐๐ฌ๐ ๐ trial of oral VK2735 later in 2026.๐ ๐๐ก๐ฒ ๐๐ญ ๐๐๐ญ๐ญ๐๐ซ๐ฌ:โค VK3019 expands Viking's pipeline in the rapidly growing ๐จ๐๐๐ฌ๐ข๐ญ๐ฒ treatment market.โค DACRA therapies could complement ๐๐๐-๐ and GLP-1/GIP weight-loss medicines.โค Success could provide additional ๐ฅ๐จ๐ง๐ -๐ญ๐๐ซ๐ฆ ๐ฐ๐๐ข๐ ๐ก๐ญ-๐ฆ๐๐ง๐๐ ๐๐ฆ๐๐ง๐ญ options for patients.๐ ๐๐ฑ๐ฉ๐๐ซ๐ญ ๐๐ญ๐๐ญ๐๐ฆ๐๐ง๐ญ:โค "The initiation of VK3019's Phase 1 study marks an important expansion of our portfolio of novel therapies designed to optimize the weight loss journey for patients and their physicians." โ ๐๐ซ๐ข๐๐ง ๐๐ข๐๐ง, Ph.D., Chief Executive Officer of Viking Therapeutics.โค "Therapies that target amylin and calcitonin receptors may potentially be used alone or in combination with GLP-1 or dual GLP-1/GIP agonists to improve the induction of weight loss as well as for longer-term weight management." โ ๐๐ซ๐ข๐๐ง ๐๐ข๐๐ง.โค "Broadening the potential treatment options is crucial to meeting the diverse needs of individuals seeking safe and sustainable weight loss." โ ๐๐ซ๐ข๐๐ง ๐๐ข๐๐ง.
GLOBAL PARTNERS LP 9.50% FIXED RATE CUM RED PERP SER B
GLP-B----
Share your thoughts
What's on your mind?
0 / 2,000
- T
GLP 1 demand is exploding because everyone wants the easy button, quick fix, no effort, no discipline
I dropped 50 pounds in 5 monthsNo drugsJust sleep, clean diet, resistance training, consistencyThere is no secret, just boring execution every single dayIf I can do it, anyone canThis is not a flex, this is proof that discipline still works - M
$Hims & Hers Health(HIMS.US) holds leading scale in US direct-to-consumer personalized telehealth (~2x the size of many #2 players).
Core moat includes data flywheel (labs with 130+ biomarkers), high customer trust/brand, low churn via subscriptions, and supplier networks. Competitors include Ro/Roman, traditional telehealth, and branded pharma direct channels.
Threats from GLP-1 price competition and compounding regulations are being actively mitigated via branded pivots and diversification. Market share continues expanding in core categories.
@Bridge Buzz SG
NewDiscussionZones - H
I still believe metals are finishing off its third wave which will be followed by a fourth wave retreat coinciding with a full risk on market favouring high betas and cryptos.
FeaturedYour Tuesday Market Brief is Here: Crypto at $95K, Maduro in Court & OpenAIโs $20K Robot ๐ฐ๐ Hey brilliant investors! ๐ 2026 is already roaring with moves โ from courts to commodities, AI to weight-loss pills. Hereโs whatโs hot in the markets today (Jan 6, 2026):
